Lacosamide Ucb

Lacosamide, the active ingredient in Lacosamide Ucb, is a sodium channel blocker presented as an injection for intravenous use. It is indicated as adjunctive therapy for partial‑onset seizures in patients with epilepsy. The formulation is intended for use in acute care settings where rapid plasma concentrations are required.

GNH USA supplies Lacosamide Ucb as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. Our distribution network ensures timely delivery and compliance with local regulatory requirements.

Lacosamide is an antiepileptic drug used as adjunctive therapy for focal seizures.

Partial‑onset seizures (adults): adjunctive therapy to reduce seizure frequency. Partial‑onset seizures (children ≥4 years): adjunctive therapy to reduce seizure frequency. Focal seizures with secondary generalisation: adjunctive therapy to improve seizure control.

Lacosamide may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Nausea: mild to moderate upset stomach. - Fatigue: feeling unusually tired or weak. - Headache: mild to moderate cranial pain. - Diplopia: transient double vision.

Serious or Rare Side Effects: - Cardiac conduction abnormalities: PR‑interval prolongation or arrhythmia. - Suicidal ideation: thoughts of self‑harm requiring immediate evaluation. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Respiratory depression: reduced breathing effort, especially with CNS depressants. - Anaphylaxis: acute allergic reaction with airway compromise.

When prescribing Lacosamide, clinicians should consider several safety factors.

Renal impairment: dose may require adjustment based on renal function. Hepatic impairment: monitor liver enzymes and consider dose modification. Cardiac conduction: obtain baseline ECG and monitor for PR‑interval changes. Pregnancy: use only if potential benefit justifies potential risk to the fetus. Drug‑specific warnings: avoid abrupt discontinuation to reduce seizure recurrence risk. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Lacosamide can interact with several medication classes, requiring careful management.

Major Interactions (Avoid): - Other sodium channel blockers (e.g., carbamazepine, phenytoin): increased risk of CNS depression. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise lacosamide plasma levels. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower lacosamide exposure. - Opioids (e.g., morphine, fentanyl): heightened risk of respiratory depression. - Alcohol: additive CNS depressive effects.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): may require INR monitoring. - Antidepressants (e.g., SSRIs, SNRIs): may increase dizziness or somnolence.